AusPAR: Hepatitis B surface antigen / pertussis filamentous haemagglutinin / pertussis toxoid / poliovirus / tetanus protein / tetanus toxoid / Diphtheria toxoid / Haemophilus type B polysaccharide
Related information
- Australian Public Assessment Reports for prescription medicines (AusPARs)
- Browse AusPARs by active ingredient
- Browse AusPARs by product name
- Browse AusPARs by sponsor
How to access a pdf or Word document
*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.
Australian Public Assessment Report
28 January 2015
| AusPAR | |
|---|---|
| Active Ingredient | Hepatitis B surface antigen / pertussis filamentous haemagglutinin / pertussis toxoid / poliovirus / tetanus protein / tetanus toxoid / Diphtheria toxoid / Haemophilus type B polysaccharide
|
| Product Name | Hexaxim
|
| Sponsor | Sanofi Aventis Australia Pty Ltd
|
| Submission Number | PM-2013-02800-1-2
|
| Submission Type | New biological entity
|
| Decision | Approved
|
| AusPAR Date | 12 January 2015
|
| Publication Date | 28 January 2015 |